{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:56:21Z","timestamp":1790657781330,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03706-0","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:53:46Z","timestamp":1784184826000},"page":"4646-4667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Safety and Effectiveness of Cabotegravir in People Living with HIV: Interim Report of a Post-marketing Surveillance in Japan"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5027-250X","authenticated-orcid":false,"given":"Yoichiro","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1154-7090","authenticated-orcid":false,"given":"Takako","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8195-0594","authenticated-orcid":false,"given":"Yuko","family":"Maeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8616-8835","authenticated-orcid":false,"given":"Akemi","family":"Sebata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Ibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5855-2084","authenticated-orcid":false,"given":"Akiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"3706_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.35772\/ghm.2019.01030","volume":"2","author":"S Oka","year":"2020","unstructured":"Oka S, Ikeda K, Takano M, et al. Pathogenesis, clinical course, and recent issues in HIV-1-infected Japanese hemophiliacs: a three-decade follow-up. Glob Health Med. 2020;2:9\u201317.","journal-title":"Glob Health Med"},{"key":"3706_CR2","unstructured":"AIDS Surveillance Committee, Ministry of Health, Labour and Welfare. Annual report on AIDS trends. 2024. https:\/\/api-net.jfap.or.jp\/status\/japan\/data\/2024\/nenpo\/r06gaiyo.pdf. Accessed Oct 2025."},{"key":"3706_CR3","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. department of health and human services, panel on antiretroviral guidelines for adults and adolescents\u2014a working group of the NIH office of AIDS research advisory council. 2024. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf. Accessed Sep 2025."},{"key":"3706_CR4","unstructured":"Research Group Aiming to Build Team Medical Care and Improve Medical Standards for HIV Infection and Hemophilia. Anti-HIV treatment guideline 2025 (in Japanese). https:\/\/hiv-guidelines.jp\/pdf\/hiv_guideline2025.pdf. Accessed Sep 2025."},{"key":"3706_CR5","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240031593. Accessed Sep 2025."},{"key":"3706_CR6","unstructured":"European AIDS Clinical Society. Anti-HIV treatment guideline 2025. Part 1: prevention & management of HIV & related infections. 2: antiretroviral treatment & prevention. https:\/\/eacs.sanfordguide.com\/eacs-part1\/art. Accessed Sep 2025."},{"key":"3706_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00831","volume":"8","author":"SA Iacob","year":"2017","unstructured":"Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Front Pharmacol. 2017;8:831.","journal-title":"Front Pharmacol"},{"key":"3706_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.20452\/pamw.4357","volume":"128","author":"L Seyler","year":"2018","unstructured":"Seyler L, Lacor P, Allard SD. Current challenges in the treatment of HIV. Pol Arch Intern Med. 2018;128:609\u201316.","journal-title":"Pol Arch Intern Med"},{"key":"3706_CR9","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s10461-020-03055-1","volume":"25","author":"P de Los Rios","year":"2021","unstructured":"de Los Rios P, Okoli C, Castellanos E, et al. Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the positive perspectives study. AIDS Behav. 2021;25:961\u201372.","journal-title":"AIDS Behav"},{"key":"3706_CR10","unstructured":"ViiV Healthcare ULC. Vocabria\u00ae and Cabenuva\u00ae product monograph including patient medication information. 2021. https:\/\/viivhealthcare.com\/content\/dam\/cf-viiv\/viiv-healthcare\/en_GB\/medicines\/CABENUVA-VOCABRIA-PM-26-Mar-2021.pdf. Accessed Sep 2025."},{"key":"3706_CR11","unstructured":"European Medicines Agency. Vocabria\u00ae prescribing information. Updated March 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vocabria. Accessed Sep 2025."},{"key":"3706_CR12","unstructured":"ViiV Healthcare. Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/212888s003lbl.pdf. Accessed Sep 2025."},{"key":"3706_CR13","unstructured":"ViiV Healthcare. Vocabria tablets (30 mg) package insert. 4th edition. 2024. https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00070466.pdf. Accessed Sep 2025."},{"key":"3706_CR14","unstructured":"ViiV Healthcare. Vocabria tablets (30 mg) interview form. 5th edition. 2025. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/ja_JP\/products-info\/viiv\/vocabria\/vocabria_tab-if.pdf. Accessed Sep 2025."},{"key":"3706_CR15","unstructured":"ViiV Healthcare. Vocabria aqueous suspension for intramuscular injection (400 mg, 600 mg) package insert. 4th edition. 2024. https:\/\/s3-ap-northeast-1.amazonaws.com\/medley-medicine\/prescriptionpdf\/166272_6250408A1028_1_04.pdf. Accessed Sep 2025."},{"key":"3706_CR16","unstructured":"ViiV Healthcare. Vocabria aqueous suspension for intramuscular injection (400 mg, 600 mg) interview form. 5th edition. 2025. https:\/\/www.pmda.go.jp\/PmdaSearch\/rdDetail\/iyaku\/6250408A1028_1. Accessed Sep 2025."},{"key":"3706_CR17","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin C, Arasteh K, G\u00f3rgolas Hern\u00e1ndez-Mora M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382:1124\u201335.","journal-title":"N Engl J Med"},{"key":"3706_CR18","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112\u20133.","journal-title":"N Engl J Med"},{"key":"3706_CR19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","volume":"85","author":"G Rizzardini","year":"2020","unstructured":"Rizzardini G, Overton ET, Orkin C, et al. Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. J Acquir Immune Defic Syndr. 2020;85:498\u2013506.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3706_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab439","volume":"8","author":"GHR Smith","year":"2021","unstructured":"Smith GHR, Henry WK, Podzamczer D, et al. Efficacy, safety, and durability of long-acting cabotegravir and rilpivirine in adults with human immunodeficiency virus type 1 infection: 5-year results from the LATTE-2 study. Open Forum Infect Dis. 2021;8:ofab439.","journal-title":"Open Forum Infect Dis"},{"key":"3706_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","volume":"36","author":"S Swindells","year":"2022","unstructured":"Swindells S, Lutz T, Van Zyl L, et al. Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS. 2022;36:185\u201394.","journal-title":"AIDS"},{"key":"3706_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/COH.0000000000000708","volume":"17","author":"SH Bares","year":"2022","unstructured":"Bares SH, Scarsi KK. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. Curr Opin HIV AIDS. 2022;17:22\u201331.","journal-title":"Curr Opin HIV AIDS"},{"key":"3706_CR23","unstructured":"HIV-related drug co-operative survey. HRD website (in Japanese). https:\/\/www.hrd.gr.jp\/index.html. Accessed Sep 2025."},{"key":"3706_CR24","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1007\/s12325-021-01842-3","volume":"38","author":"H Hongo","year":"2021","unstructured":"Hongo H, Nagao T, Nakamura K, et al. Safety and effectiveness analysis of dolutegravir in patients with HIV-1: interim report of post-marketing surveillance in Japan. Adv Ther. 2021;38:4480\u2013504.","journal-title":"Adv Ther"},{"key":"3706_CR25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1089\/aid.2023.0108","volume":"40","author":"E Adachi","year":"2024","unstructured":"Adachi E, Saito M, Otani A, Koga M, Yotsuyanagi H. Favorable virological outcome, characteristics of injection site reactions, decrease in renal function biomarkers in Asian people with HIV receiving long-acting cabotegravir plus rilpivirine. AIDS Res Hum Retroviruses. 2024;40:216\u201322.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"3706_CR26","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/hiv.70096","volume":"26","author":"E Adachi","year":"2025","unstructured":"Adachi E, Minami R, Shirano M, et al. Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: a multicentre study of efficacy, safety and biomarker dynamics. HIV Med. 2025. https:\/\/doi.org\/10.1111\/hiv.70096.","journal-title":"HIV Med"},{"key":"3706_CR27","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cid\/ciad020","volume":"76","author":"ET Overton","year":"2023","unstructured":"Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis. 2023;76:1646\u201354.","journal-title":"Clin Infect Dis"},{"key":"3706_CR28","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s40121-025-01178-3","volume":"14","author":"C Dannenberg","year":"2025","unstructured":"Dannenberg C, Matthews H, H\u00fcfner A, et al. Long-term real-world use of cabotegravir\/rilpivirine: adherence and virological efficacy over a 44-month observation period. Infect Dis Ther. 2025;14:1775\u201397.","journal-title":"Infect Dis Ther"},{"key":"3706_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/25787489.2019.1661696","volume":"20","author":"M Murray","year":"2019","unstructured":"Murray M, Pulido F, Mills A, et al. Patient-reported tolerability and acceptability of cabotegravir\u2009+\u2009rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. HIV Res Clin Pract. 2019;20:111\u201322.","journal-title":"HIV Res Clin Pract"},{"key":"3706_CR30","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","volume":"24","author":"M Murray","year":"2020","unstructured":"Murray M, Antela A, Mills A, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks. AIDS Behav. 2020;24:3533\u201344.","journal-title":"AIDS Behav"},{"key":"3706_CR31","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40271-021-00524-0","volume":"14","author":"V Chounta","year":"2021","unstructured":"Chounta V, Overton ET, Mills A, et al. Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2M). Patient-Patient-Cent Outcomes Res. 2021;14:849\u201362.","journal-title":"Patient-Patient-Cent Outcomes Res"},{"key":"3706_CR32","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1186\/s12879-024-09904-x","volume":"24","author":"K Konishi","year":"2024","unstructured":"Konishi K, Onozuka D, Okubo M, et al. Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting. BMC Infect Dis. 2024;24:979.","journal-title":"BMC Infect Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03706-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03706-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03706-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:15:07Z","timestamp":1790655307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03706-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3706"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03706-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors (Yoichiro Yoshikawa, Takako Nagao, Tomoko Matsukawa, Miwako Suzuki, Akemi Sebata, Yuko Maeno, Shiro Ibe, Akiko Fukuda and Dong Wang) are employees of ViiV Healthcare K.K.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This post-marketing surveillance was conducted by CMIC HOLDINGS Co., Ltd. (Tokyo, Japan) on behalf of ViiV Healthcare K.K. in compliance with applicable Japanese regulations, including the Ministerial Ordinance on Good Post-marketing Study Practice (GPSP; MHLW No. 171, December 20, 2004), its subsequent amendments, and related notifications. The study protocol was reviewed and approved by the Pharmaceuticals and Medical Devices Agency, the Japanese regulatory authority, and subsequently approved by the ethics committees of each participating institution. In accordance with GPSP regulations, written informed consent was not required for post-marketing surveillance; however, treating physicians provided participants with explanations regarding HIV treatment drugs, including antiretroviral drugs and other HIV-related medications, and obtained verbal consent prior to participation.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}